SCHEMBL8466367

SCHEMBL8466367

CC(C)(C)Oc1cc(C=O)ccc1O

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.66
ALDH5A1 P51649 2/20 0.66
ABAT P80404 2/20 0.66
TRIM24 O15164 1/20 0.66
HPGD P15428 1/20 0.66
TDP1 Q9NUW8 1/20 0.66
TRIM33 Q9UPN9 1/20 0.66
KDM4E B2RXH2 2/20 0.52
PTGS2 P35354 1/20 0.52
RAB9A P51151 1/20 0.52
AOX1 Q06278 1/20 0.51
TSHR P16473 1/20 0.47
XDH P47989 1/20 0.46
APP P05067 3/20 0.44
EPHX2 P34913 1/20 0.44
TRPA1 O75762 1/20 0.43
TTR P02766 2/20 0.43
CYP1A2 P05177 1/20 0.42
ALOX5 P09917 1/20 0.42
CYP2D6 P10635 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20869201 0.86 ALDH1A1 (0.66) ALDH1A1ALDH5A1ABATTRIM24HPGD
SCHEMBL29991604 0.83 ALDH1A1 (0.57) ALDH1A1ALDH5A1ABATTRIM24HPGD
SCHEMBL18883604 0.83 ALDH1A1 (0.57) ALDH1A1ALDH5A1ABATTRIM24HPGD
SCHEMBL856737 0.82 APP (0.63) ALDH1A1ALDH5A1ABATTRIM24HPGD
SCHEMBL30203126 0.82 APP (0.63) ALDH1A1ALDH5A1ABATTRIM24HPGD
SCHEMBL686127 0.82 TRPA1 (0.66) ALDH1A1ALDH5A1ABATTRIM24HPGD
Vanillin SCHEMBL1213 0.79 ALDH1A1 (1.00) ALDH1A1ALDH5A1ABATTRIM24HPGD
Vanillin SCHEMBL29354839 0.79 ALDH1A1 (1.00) ALDH1A1ALDH5A1ABATTRIM24HPGD
Vanillin SCHEMBL720723 0.79 ALDH1A1 (1.00) ALDH1A1ALDH5A1ABATTRIM24HPGD
SCHEMBL16972475 0.79 APP (0.70) ALDH1A1HPGDTDP1KDM4EPTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0709361-B1 Process for the preparation of isovanilline RHODIA CHIMIE SA (FR) 1999-02-03 EP claimed
US-5786516-A Process for the preparation of isovanillin RHONE-POULENC CHIMIE (FR) 1998-07-28 US claimed
US-5648552-A Process for the preparation of isovanillin RHONE-POULENC CHIMIE (FR) 1997-07-15 US claimed
EP-0709361-A1 Process for the preparation of isovanilline RHONE-POULENC CHIMIE (FR) 1996-05-01 EP claimed
US-12466795-B2 Isoindoline compositions and methods for treating neurodegenerative disease COGNITION THERAPEUTICS, INC. (US) 2025-11-11 US disclosed
US-20240150288-A1 ISOINDOLINE COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE COGNITION THERAPEUTICS, INC. (US) 2024-05-09 US disclosed
US-11691947-B2 Isoindoline compositions and methods for treating neurodegenerative disease COGNITION THERAPEUTICS, INC. (US) 2023-07-04 US disclosed
US-11691947-B2 Isoindoline compositions and methods for treating neurodegenerative disease COGNITION THERAPEUTICS, INC. (US) 2023-07-04 US disclosed
US-11691947-B2 Isoindoline compositions and methods for treating neurodegenerative disease COGNITION THERAPEUTICS, INC. (US) 2023-07-04 US disclosed
EP-4023294-A1 ISOINDOLINE COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE Cognition Therapeutics, Inc. (US) 2022-07-06 EP disclosed
EP-4023294-A1 ISOINDOLINE COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE Cognition Therapeutics, Inc. (US) 2022-07-06 EP disclosed
EP-3498692-B1 ISOINDOLINE COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE AND MACULAR DEGENERATION COGNITION THERAPEUTICS INC (US) 2022-03-16 EP disclosed
WO-2015116923-A1 ISOINDOLINE COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE COGNITION THERAPEUTICS, INC. (US) 2015-08-06 WO disclosed
WO-2015116923-A1 ISOINDOLINE COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE COGNITION THERAPEUTICS, INC. (US) 2015-08-06 WO disclosed
CN-100361994-C Tetraphenyl porphyrin derivative and its application in organic electroluminescent device UNIV JILIN (CN) 2008-01-16 CN disclosed
CN-1631890-A Tetraphenyl porphyrin derivative and its application in organic electroluminescent device UNIV JILIN (CN) 2005-06-29 CN disclosed
EP-0709361-B1 Process for the preparation of isovanilline RHODIA CHIMIE SA (FR) 1999-02-03 EP disclosed
US-5786516-A Process for the preparation of isovanillin RHONE-POULENC CHIMIE (FR) 1998-07-28 US disclosed
US-5648552-A Process for the preparation of isovanillin RHONE-POULENC CHIMIE (FR) 1997-07-15 US disclosed
EP-0709361-A1 Process for the preparation of isovanilline RHONE-POULENC CHIMIE (FR) 1996-05-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11691947-B2 Isoindoline compositions and methods for treating neurodegenerative disease TMEM97, SLC18A2, PSD ALDH1A1 4160/4885ALDH5A1 3758/4885ABAT 1729/4885
US-20240150288-A1 ISOINDOLINE COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE TMEM97, SLC18A2, PSD ALDH1A1 4160/4885ALDH5A1 3758/4885ABAT 1729/4885
US-12466795-B2 Isoindoline compositions and methods for treating neurodegenerative disease TMEM97, SLC18A2, PSD ALDH1A1 4160/4885ALDH5A1 3758/4885ABAT 1729/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.